Literature DB >> 18984852

Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype.

Xiuying Bai1, Qiu Dinghong, Dengshun Miao, David Goltzman, Andrew C Karaplis.   

Abstract

Transgenic mice overexpressing fibroblast growth factor (FGF23) (R176Q) (F(Tg)) exhibit biochemical {hypophosphatemia, phosphaturia, abnormal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] metabolism} and skeletal (rickets and osteomalacia) abnormalities attributable to FGF23 action. In vitro studies now implicate the aging-related factor Klotho in the signaling mechanism of FGF23. In this study, we used a mouse genetic approach to validate in vivo the pivotal role of Klotho in the metabolic and skeletal derangements associated with FGF23 (R176Q) overexpression. To this end, we crossed mice heterozygous for the hypomorphic Klotho allele (Kl(+/-)) to F(Tg) mice and obtained F(Tg) transgenic mice homozygous for the Kl-hypomorphic allele (F(Tg)/Kl(-/-)). Mice were killed on postnatal day 50, and serum and tissues were procured for analysis and comparison with F(Tg), wild-type, and Kl(-/-) controls. From 4 wk onward, F(Tg)/Kl(-/-) mice were clearly distinguishable from F(Tg) mice and exhibited a striking phenotypic resemblance to the Kl(-/-) controls. Serum analysis for calcium, phosphorus, parathyroid hormone, 1,25(OH)(2)D(3), and alkaline phosphatase activity confirmed the biochemical similarity between the F(Tg)/Kl(-/-) and Kl(-/-) mice and their distinctness from the F(Tg) controls. The characteristic skeletal changes associated with FGF23 (R176Q) overexpression were also dramatically reversed by the absence of Klotho. Hence the wide, unmineralized growth plates and the osteomalacic abnormalities apparent in trabecular and cortical bone were completely reversed in the F(Tg)/Kl(-/-) mice. Nevertheless, independent actions of Klotho on bone were suggested as manifested by alterations in mineralized bone, and in cortical bone volume which were observed in both the Kl(-/-) and F(Tr)/Kl(-/-) mutants. In summary, our findings substantiate in vivo the essential role of Klotho in the mechanism of action of FGF23 in view of the fact that Klotho ablation converts the biochemical and skeletal manifestations resulting from FGF23 overexpression to a phenotype consistent with Klotho deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984852     DOI: 10.1152/ajpendo.90539.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  16 in total

Review 1.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

2.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

3.  Regulation of mineral metabolism by lithium.

Authors:  Hajar Fakhri; Ganesh Pathare; Abul Fajol; Bingbing Zhang; Thomas Bock; Reinhard Kandolf; Erwin Schleicher; Jürg Biber; Michael Föller; Undine E Lang; Florian Lang
Journal:  Pflugers Arch       Date:  2013-09-07       Impact factor: 3.657

Review 4.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 5.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

6.  Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.

Authors:  Loan Nguyen-Yamamoto; Andrew C Karaplis; Rene St-Arnaud; David Goltzman
Journal:  J Am Soc Nephrol       Date:  2016-08-17       Impact factor: 10.121

Review 7.  The role of FGF23 in CKD--with or without Klotho.

Authors:  Hirotaka Komaba; Masafumi Fukagawa
Journal:  Nat Rev Nephrol       Date:  2012-06-19       Impact factor: 28.314

Review 8.  Disorders of phosphorus homeostasis.

Authors:  Richard Lee; Thomas J Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-12       Impact factor: 3.243

Review 9.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 10.  FGF-23 in bone biology.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2009-12-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.